May 2nd 2024
This month's review showcases the ongoing efforts to enhance patient care through innovative treatments and comprehensive management strategies.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Navigating Newer Approaches to Managing IgA Nephropathy
April 14, 2024
Register Now!
Addressing Healthcare Inequities: Tailoring Management Plans to Address Healthcare Disparities in Cystic Fibrosis
View More
Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies
View More
Show Me the Data: Bridging Clinical Gaps in Later Lines of Metastatic CRC… It’s Easy as VEGFR1, 2, 3!
April 17, 2024
View More
9th Annual School of Gastrointestinal Oncology® (SOGO®)
View More
FDA Approves High-Concentrate, Citrate-Free Formulation of Biosimilar Adalimumab-adbm
The current approval is based on the VOLTAIRE-HCLF clinical trial, which examined the bioavailability of high-concentration (100 mg/mL) and low-concentration (50 mg/mL) formulations of adalimumab-adbm.